Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05279755 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate the Safety and Pharmacokinetics of Single and Multiple Doses of Prosetin in Healthy Volunteers and Participants With ALS
A Phase 1 study of Amyotrophic Lateral Sclerosis, sponsored by ProJenX.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 72
- Enrollment target
- 4
- Study locations
NCT05279755 is a Phase 1 study of Amyotrophic Lateral Sclerosis that is actively recruiting participants, run by ProJenX. The registered enrollment target is 72 participants, below the 897-participant average among 102 other Amyotrophic Lateral Sclerosis trials with a reported enrollment target (92% lower). The trial reports 4 study locations across 4 states.
The verdict
NCT05279755, a Phase 1 study of Amyotrophic Lateral Sclerosis, is actively recruiting participants, sponsored by ProJenX.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 72 participants
- Enrollment target
- 4
- Study locations
Study Summary
The primary purpose of this study is to evaluate the safety and tolerability of prosetin in healthy volunteers and participants with ALS.
Conditions Studied
Interventions
- DRUG placebo
- DRUG prosetin
Study Locations (4)
Massachusetts
- Massachusetts General Hospital - Boston
Texas
- Worldwide Clinical Trials Early Phase Services - San Antonio
Quebec
- The Neuro - Montréal Neurological Institute-Hospital - Montreal
Utrecht
- University Medical Center Utrecht - Utrecht
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 72 participants |
| Start Date | 2022-02-26 |
| Est. Completion | 2026-10-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05279755
The ClinicalTrials.gov registry entry for NCT05279755 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 72 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 897-participant average among 102 other Amyotrophic Lateral Sclerosis trials with a reported enrollment target (92% lower). The listed sponsor is ProJenX, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Amyotrophic Lateral Sclerosis appearing as the primary indexed condition, and to 2 interventions - of which placebo is the first listed.
NCT05279755 reports 4 study locations spanning 4 distinct geographic areas - top geographies include Massachusetts, Texas, Quebec.
Frequently Asked Questions
What is clinical trial NCT05279755 about?
NCT05279755 is a clinical study titled "A Study to Evaluate the Safety and Pharmacokinetics of Single and Multiple Doses of Prosetin in Healthy Volunteers and Participants With ALS". The primary purpose of this study is to evaluate the safety and tolerability of prosetin in healthy volunteers and participants with ALS.
What is the current status of trial NCT05279755?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 72 participants. The study started on 2022-02-26. Estimated completion is 2026-10-31.
What conditions does trial NCT05279755 study?
This clinical trial studies the following conditions: Amyotrophic Lateral Sclerosis.
What interventions are being tested in trial NCT05279755?
The interventions under investigation include: placebo (DRUG), prosetin (DRUG).
Who is sponsoring clinical trial NCT05279755?
This trial is sponsored by ProJenX, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05279755 being conducted?
This trial has 4 study locations across Massachusetts, Texas, Quebec, Utrecht. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Amyotrophic Lateral Sclerosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Investigate the Safety and Pharmacodynamics of a Single Intrathecal Injection (IT) of INS1202 in Participants With Amyotrophic Lateral Sclerosis (ALS)
RECRUITING · Phase 1
-
Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Amisodin in Healthy Adult Subjects With Amyotrophic Lateral Sclerosis
RECRUITING · Phase 1
-
Study is to Assess the Safety and Tolerability of VTx-002 in Participants With ALS
RECRUITING · Phase 1
-
Acamprosate in C9orf72 Hexanucleotide Repeat Expansion Amyotrophic Lateral Sclerosis (ACALS)
ACTIVE NOT RECRUITING · Phase 1
-
Regulatory T Cells for Amyotrophic Lateral Sclerosis
ACTIVE NOT RECRUITING · Phase 1
-
CNS10-NPC-GDNF Delivered to the Motor Cortex for ALS
ACTIVE NOT RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.